Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Aravive begins Phase Ib part of ovarian cancer drug trial

Malignant ovarian tumours with induced expression of carbonyl reductase show spontaneous regression. Credit: Libertas Academica.

  • Aravive

Go Top